期刊文献+

新型广谱头孢菌素类抗菌药物头孢吡普 被引量:5

A novel broad-spectrum cephalosporin ceftobiprole
下载PDF
导出
摘要 随着耐甲氧西林金葡萄球菌、耐药金黄色葡萄球菌、耐青霉素肺炎链球菌和耐万古霉素肠球菌显著增加,细菌耐药性成为近年来一个重大难题。Ceftobiprole是第一个对耐甲氧西林金葡萄球菌(MRSA)和万古霉素耐药金黄色葡葡球菌(VRSA)有效的广谱头孢菌素类抗生素。现对其作用机制、合成路线、体外抗菌活性、药动学特性、临床试验等方面作一综述。 Antimicrobial resistance has become a significant problem over the past decade with marked increases in the incidence of MRSA, intermediate- and high level resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant enterococci. Ceftobiprole was the first of a new class of broad- spectrum cephalosporin antibiotics that had potent antibacterial activity towards methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA). This review detailed its mechanism of action, synthesis methods, antibacterial activities in vivo, pharmacokinetic profle and clinical trials.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2011年第9期641-650,共10页 Chinese Journal of Antibiotics
关键词 CEFTOBIPROLE 合成路线 抗菌活性 临床试验 Ceftobiprole Synthesis methods Antibacterial activity Clinical trials
  • 相关文献

参考文献41

  • 1傅德才,狄蕊,李彬.头孢菌素类抗生素的研究进展[J].河北师范大学学报(自然科学版),2006,30(6):693-697. 被引量:17
  • 2张致平.β-内酰胺类抗生素研究的进展(Ⅰ)[J].中国抗生素杂志,2000,25(2):81-86. 被引量:39
  • 3Anderson S D, Gums J G. Ceftobiprole: an extended- spectrum anti-methicillin resistant Staphylococcus aureus Cephalosporin[J]. Ann Pharmacother, 2008, 42(6): 806-816.
  • 4Ali A E1 Solh. Ceftobiprole: a new broad spectrum cephalosporin[J]. Expert Opin Pharmacother, 2009, 10(10): 1675-1686.
  • 5Jones M E. In-vitro profile of a new β-lactam, ceflobiprole, with activity against methicillin resistant Staphylococcus aureus[J]. Clin Microbiol Inject, 2007, 13 (S2): 17-24.
  • 6Adis R&D profile. Ceftobiprole medocaril[J]. Drugs R D, 2006, 7(5): 305-311.
  • 7Bush K, Heep M, Macielag M J, et al. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy[J]. Expert Opin Investig Drugs, 2007,16(4): 419-429.
  • 8Neuner E A, Ritchie D J, Micek S T. New antibiotics for healthcare-associated pneumonia[J]. Semin Respir Crit Care Med, 2009, 30(1): 92-101.
  • 9Lim D, Strynadka N C. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureu[J]. Nat Struct Biol, 2002, 9(11) 870-876.
  • 10Livermore D M. Can beta-lactams be re-engineered to beat MRSA[J]. Clin Microbiol Infect, 2006, 12(Suppl 2): 11 - 16.

二级参考文献44

  • 1卫敬星.意象复叠与符号隐喻:微电影《龙头》解读[J].电影评介,2013(10):42-43. 被引量:2
  • 2BOSSO JA.The antimicrobial armamentarium:evaluating current and future treatment options[J].Pharmacotherapy,2005,25 (10 Pt 2):55S -62S.
  • 3SCHMIDT-IOANAS M,DE ROUX A,LODE H.New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient[J].Curr Opin Crit Care,2005,11 (5):481-486.
  • 4HEBEISEN P,HEINZE-KRAUSS I,ANGEHRN P,et al.In vitro and in vivo properties of Ro 63-9141,a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci[J].Antimicrob Agents Chemother,2001,45 (3):825-836.
  • 5VON EIFF C,FRIEDRICH AW,BECKER K,et al.Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes[J].Antimicrob Agents Chemother,2005,49 (10):4372-4374.
  • 6BOGDANOVICH T,EDNIE LM,SHAPIRO S,et al.Antistaphylococcal activity of ceftobiprole,a new broad-spectrum cephalosporin[J].Antimicrob Agents Chemother,2005,49(10):4210 -4219.
  • 7KOSOWSKA K,HOELLMAN DB,LIN G,et al.Antipneumococcal activity of ceftobiprole,a novel broad-spectrum cephalosporin[J].Antimicrob Agents Chemother,2005,49 (5):1932-1942.
  • 8DESHPANDE L,RHOMBERG PR,FRITSCHE TR,et al.Bactericidal activity of BAL9141,a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates [J].Diagn Microbiol Infect Dis,2004,50 (1):73 -75.
  • 9JONES RN,DESHPANDE LM,MUTNICK AH,et al.In vitro evaluation of BAL9141,a novel parenteral cephalosporin active against oxacillin-resistant staphylococci[J].J Antimicrob Chemother,2002,50 (6):915-932.
  • 10APPELBAUM PC,JACOBS MR.Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria[J].Curr Opin Microbiol,2005,8 (5):510 -517.

共引文献54

同被引文献59

  • 1于守汎.头孢哌酮与舒巴坦复合制剂Sulperazone[J].国外医药(抗生素分册),1997,18(3):220-224. 被引量:7
  • 2蔡芸,王睿.新型头孢菌素类抗生素ceftobiprole[J].中国新药杂志,2006,15(17):1504-1507. 被引量:4
  • 3尤启东.药物化学[M].北京:化学工业出版社,2004.178,409.
  • 4仲兆金.新的抗MRSA β-内酰胺类抗生素[J].国外医药(抗生素分册),2007,28(5):202-204. 被引量:4
  • 5Jones ME. In-vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin resistant Staphylococcus aureus[J]. Clin Microbiol Infect, 2007,13(S2) : 17.
  • 6Adis Intemation Limited. Ceftobiprole Medocaril: BAL5788, JNJ30982081, JNJ30982081, RO65-5788, RO655788[J]. Drugs R D, 2006,7 (5) : 305.
  • 7Bush K, Heep M, Macielag MJ, et al. Anti-MRSAβ-lactams in development, with a focus on ceflobiprole: the first anti-MRSA fl-lactam to demonstrate clinical efficacy [J]. Expert Opin lnvestig Drugs, 2007,16 (4) : 419.
  • 8Lim D, Strynadka NC. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureu[J]. Nat Struct Biol, 2002,9 ( 11 ) : 870.
  • 9Livermore DM. Can beta-lactams be re-engineered to beat MRSA[J]. Clin Microbiollnfect, 2006,12(2) : 11.
  • 10Rouse MS, Steckelberg JM, Patel R, et al. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection[J]. Diagn Microbiol lnfect Dis, 2007,58 (3) : 363.

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部